| 2019-12-06 14:20:19|
GRFS 14:20 12/06 12/06/19
Grifols higher after new data show reduction in Alzheimer's progression
Grifols shares moved higher after the company presented its latest Alzheimer's clinical trial data at the Clinical Trials on Alzheimer's Disease Conference. New neuroimaging data results from the Ambar clinical trial show the reduction in the progression of the disease in patients with mild-to-moderate Alzheimer's disease, Grifols announced. The neuroimaging, which was measured by the FDG-PET1 technique, shows "positive" results particularly in patients receiving both albumin and immunoglobulin, according the company. In comparison with the placebo group, these patients had less reduction of brain glucose metabolism over the 14 months of the clinical trial. "This suggests that neuronal damage was reduced in these patients," Grifols said. The company added that it will soon meet with the FDA to discuss the Ambar clinical development program and the design of a successive Ambar II trial "that will deepen and complement the just-concluded one." Shares of Grifols are up 74c to $23.12 in afternoon trading.
See Street Research during your Free Trial